<DOC>
	<DOCNO>NCT02204475</DOCNO>
	<brief_summary>This randomize , multi-site , open-label trial fixed-dose combination Grazoprevir ( MK-5172 ) Elbasvir ( MK-8742 ) versus Boceprevir ( BOC ) / Pegylated Interferon ( P ) Ribavirin ( R ) treatment-naive prior treatment failure genotype ( GT ) 1 hepatitis C virus ( HCV ) -infected participant . The primary hypothesis proportion treatment-naive ( TN ) prior treatment failure ( PTF ) participant treat grazoprevir + elbasvir achieve sustain virologic response ( undetectable HCV ribonucleic acid [ RNA ] ) 12 week end study therapy ( SVR12 ) great proportion BOC/PR-treated participant achieve SVR12 .</brief_summary>
	<brief_title>Grazoprevir ( MK-5172 ) /Elbasvir ( MK-8742 ) Versus Boceprevir/Pegylated Interferon/Ribavarin Chronic Hepatitis C Infection ( MK-5172-066 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Has HCV RNA ≥ 10,000 IU/mL time screening Has document chronic HCV GT 1 evidence nontypeable mixed GT infection Is cirrhotic noncirrhotic Has HCV treatment status treatment naïve , PR null responder ; PR partial responder ; prior PR relapser If human immunodeficiency virus ( HIV ) coinfected ( HIV1 ) must naïve treatment antiretroviral therapy ( ART ) plan initiate ART treatment participate trial , HIV ART least 8 week prior trial entry ( change HIV regimen allow within 4 week registration ) ; must also least one viable antiretroviral therapy alternative beyond current regimen event HIV virologic failure development antiretroviral drug resistance Use acceptable method contraception childbearing potential Has evidence decompensated liver disease manifest presence history ascites , esophageal gastric variceal bleeding , hepatic encephalopathy sign symptom advance liver disease Is coinfected hepatitis B virus ( e.g. , hepatitis B surface antigen [ HBsAg ] positive ) Has history malignancy ≤5 year prior sign inform consent except adequately treat basal cell squamous cell skin cancer situ cervical cancer carcinoma situ ; evaluation active suspect malignancy Has cirrhosis liver image within 6 month Day 1 show evidence hepatocellular carcinoma ( HCC ) evaluation HCC Has preexist psychiatric condition ( ) Has clinicallyrelevant drug alcohol abuse within 12 month screen Is female pregnant breastfeeding , expect become pregnant donate egg Day 1 throughout treatment least 6 month last dose study medication , longer dictate local regulation ; male subject plan impregnate provide sperm donation Has preexisting condition prestudy laboratory abnormality , electrocardiogram ( ECG ) abnormality history illness , , opinion investigator , might confound result trial pose additional risk administer study drug ( ) subject Has lifethreatening severe AE ( SAE ) screen period Has evidence history chronic hepatitis cause HCV , include limited nonalcoholic steatohepatitis ( NASH ) , druginduced hepatitis , autoimmune hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>